ZOLL Respicardia

ZOLL Respicardia is a medical technology company dedicated to developing solutions for Central Sleep Apnea (CSA), a serious sleep-related breathing disorder. Founded in 2006 and acquired by ZOLL Medical Corporation in 2021, the company aims to meet the clinical needs of patients with CSA, especially those with reduced cardiac function. The flagship product, the remedē® System, is an implantable neurostimulator device that restores normal breathing patterns during sleep for patients with moderate to severe CSA. Approved by the FDA in October 2017, it is the only implantable device in the U.S. for this condition. The system stimulates the phrenic nerve to regulate breathing, improving sleep quality and alleviating symptoms like chronic fatigue and excessive daytime sleepiness. ZOLL Respicardia serves healthcare providers, including cardiologists and sleep specialists, to enhance patient outcomes for those affected by CSA. By integrating the remedē® System into clinical practice, the company aims to improve the quality of life for over one million patients in the U.S.

• Employees 94
• Founded 2006